Although still at the preclinical stage, several targets for the treatment of HCC, such as CBP (CREB binding protein) (145) and SIRT6 (Sirtuin 6), which are involved in oncogenic gene regulation (146), have been successfully degraded in vitro or in vivo in mouse models, resulting in reduced tumor progression. Here, CREBBP is linked to neoplasm.